177lu-dota-fapi
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 13, 2021 (NCT04849247)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06659705 | Phase 2 | Jan 30, 2025 | Curie Institute |
| NCT06081322 | Phase 1 | Sep 1, 2023 | Zhejiang University |
| NCT05963386 | Phase 1 | Feb 22, 2023 | Xiamen University |
| NCT05400967 | Early Phase 1 (Phase 1) | Jan 1, 2022 | Chinese Academy of Medical Sciences |
| NCT04849247 | Phase 1 | Apr 13, 2021 | Xiamen University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xiamen University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Curie Institute | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1